Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Intervention with citrus flavonoids reverses obesity and improves metabolic syndrome and atherosclerosis in obese Ldlr-/- mice.

Burke AC, Sutherland BG, Telford DE, Morrow MR, Sawyez CG, Edwards JY, Drangova M, Huff MW.

J Lipid Res. 2018 Sep;59(9):1714-1728. doi: 10.1194/jlr.M087387. Epub 2018 Jul 15.

PMID:
30008441
2.

Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient (LDLR+/- and LDLR-/-) Yucatan Miniature Pigs.

Burke AC, Telford DE, Sutherland BG, Edwards JY, Sawyez CG, Barrett PHR, Newton RS, Pickering JG, Huff MW.

Arterioscler Thromb Vasc Biol. 2018 May;38(5):1178-1190. doi: 10.1161/ATVBAHA.117.310676. Epub 2018 Feb 15.

PMID:
29449335
3.

Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in Ldlr-/- Mice by Treatment With the ATP-Citrate Lyase Inhibitor Bempedoic Acid.

Samsoondar JP, Burke AC, Sutherland BG, Telford DE, Sawyez CG, Edwards JY, Pinkosky SL, Newton RS, Huff MW.

Arterioscler Thromb Vasc Biol. 2017 Apr;37(4):647-656. doi: 10.1161/ATVBAHA.116.308963. Epub 2017 Feb 2.

PMID:
28153881
4.

PPARδ activation attenuates hepatic steatosis in Ldlr-/- mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity.

Bojic LA, Telford DE, Fullerton MD, Ford RJ, Sutherland BG, Edwards JY, Sawyez CG, Gros R, Kemp BE, Steinberg GR, Huff MW.

J Lipid Res. 2014 Jul;55(7):1254-66. doi: 10.1194/jlr.M046037. Epub 2014 May 26.

5.

Peroxisome proliferator-activated receptor δ agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice.

Bojic LA, Burke AC, Chhoker SS, Telford DE, Sutherland BG, Edwards JY, Sawyez CG, Tirona RG, Yin H, Pickering JG, Huff MW.

Arterioscler Thromb Vasc Biol. 2014 Jan;34(1):52-60. doi: 10.1161/ATVBAHA.113.301830. Epub 2013 Oct 24.

PMID:
24158519
6.

Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr⁻/⁻ mice.

Assini JM, Mulvihill EE, Sutherland BG, Telford DE, Sawyez CG, Felder SL, Chhoker S, Edwards JY, Gros R, Huff MW.

J Lipid Res. 2013 Mar;54(3):711-24. doi: 10.1194/jlr.M032631. Epub 2012 Dec 26.

7.

The oxysterol 24(s),25-epoxycholesterol attenuates human smooth muscle-derived foam cell formation via reduced low-density lipoprotein uptake and enhanced cholesterol efflux.

Beyea MM, Reaume S, Sawyez CG, Edwards JY, O'Neil C, Hegele RA, Pickering JG, Huff MW.

J Am Heart Assoc. 2012 Jun;1(3):e000810. doi: 10.1161/JAHA.112.000810. Epub 2012 Jun 22.

8.

Activation of peroxisome proliferator-activated receptor δ inhibits human macrophage foam cell formation and the inflammatory response induced by very low-density lipoprotein.

Bojic LA, Sawyez CG, Telford DE, Edwards JY, Hegele RA, Huff MW.

Arterioscler Thromb Vasc Biol. 2012 Dec;32(12):2919-28. doi: 10.1161/ATVBAHA.112.255208. Epub 2012 Sep 27.

PMID:
23023367
9.

Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance.

Mulvihill EE, Assini JM, Lee JK, Allister EM, Sutherland BG, Koppes JB, Sawyez CG, Edwards JY, Telford DE, Charbonneau A, St-Pierre P, Marette A, Huff MW.

Diabetes. 2011 May;60(5):1446-57. doi: 10.2337/db10-0589. Epub 2011 Apr 6.

10.

Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance.

Mulvihill EE, Allister EM, Sutherland BG, Telford DE, Sawyez CG, Edwards JY, Markle JM, Hegele RA, Huff MW.

Diabetes. 2009 Oct;58(10):2198-210. doi: 10.2337/db09-0634. Epub 2009 Jul 10.

11.

Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor.

Allister EM, Mulvihill EE, Barrett PH, Edwards JY, Carter LP, Huff MW.

J Lipid Res. 2008 Oct;49(10):2218-29. doi: 10.1194/jlr.M800297-JLR200. Epub 2008 Jun 27.

12.

Selective up-regulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol.

Beyea MM, Heslop CL, Sawyez CG, Edwards JY, Markle JG, Hegele RA, Huff MW.

J Biol Chem. 2007 Feb 23;282(8):5207-16. Epub 2006 Dec 23.

13.

The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin.

Telford DE, Sutherland BG, Edwards JY, Andrews JD, Barrett PH, Huff MW.

J Lipid Res. 2007 Mar;48(3):699-708. Epub 2006 Nov 27.

14.

Ankyrin G overexpression in Hutchinson-Gilford progeria syndrome fibroblasts identified through biological filtering of expression profiles.

Wang J, Robinson JF, O'Neil CH, Edwards JY, Williams CM, Huff MW, Pickering JG, Hegele RA.

J Hum Genet. 2006;51(11):934-42. Epub 2006 Oct 11.

PMID:
17033732
15.

A novel inhibitor of oxidosqualene:lanosterol cyclase inhibits very low-density lipoprotein apolipoprotein B100 (apoB100) production and enhances low-density lipoprotein apoB100 catabolism through marked reduction in hepatic cholesterol content.

Telford DE, Lipson SM, Barrett PH, Sutherland BG, Edwards JY, Aebi JD, Dehmlow H, Morand OH, Huff MW.

Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2608-14. Epub 2005 Oct 6.

PMID:
16210564
17.

Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux.

Argmann CA, Edwards JY, Sawyez CG, O'Neil CH, Hegele RA, Pickering JG, Huff MW.

J Biol Chem. 2005 Jun 10;280(23):22212-21. Epub 2005 Apr 6.

18.

Enhanced synthesis of the oxysterol 24(S),25-epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene:lanosterol cyclase: a novel mechanism for the attenuation of foam cell formation.

Rowe AH, Argmann CA, Edwards JY, Sawyez CG, Morand OH, Hegele RA, Huff MW.

Circ Res. 2003 Oct 17;93(8):717-25. Epub 2003 Sep 25.

PMID:
14512442
19.

Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB.

Telford DE, Edwards JY, Lipson SM, Sutherland B, Barrett PH, Burnett JR, Krul ES, Keller BT, Huff MW.

J Lipid Res. 2003 May;44(5):943-52. Epub 2003 Feb 1.

20.

Inhibition of the apical sodium-dependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB.

Huff MW, Telford DE, Edwards JY, Burnett JR, Barrett PH, Rapp SR, Napawan N, Keller BT.

Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1884-91.

PMID:
12426220
21.

Soya phytoestrogens, genistein and daidzein, decrease apolipoprotein B secretion from HepG2 cells through multiple mechanisms.

Borradaile NM, de Dreu LE, Wilcox LJ, Edwards JY, Huff MW.

Biochem J. 2002 Sep 1;366(Pt 2):531-9.

22.

Transforming growth factor-beta1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants.

Argmann CA, Van Den Diepstraten CH, Sawyez CG, Edwards JY, Hegele RA, Wolfe BM, Huff MW.

Arterioscler Thromb Vasc Biol. 2001 Dec;21(12):2011-8.

PMID:
11742878
23.

V region gene analysis of human IgM hybridoma monoclonal anti-Sm antibodies.

Mahmoudi M, Edwards JY, Bell DA, Cairns E.

Lupus. 1997;6(7):578-89.

PMID:
9302661
24.

The role of the immunoglobulin heavy chain in human anti-DNA antibody binding specificity.

Mahmoudi M, Denomme GA, Edwards JY, Bell DA, Cairns E.

Arthritis Rheum. 1995 Mar;38(3):389-95.

PMID:
7880195
25.

Immunoglobulin V region heavy and light chain gene sequences of the lymphoblastoid cell line GM 4672.

Denomme GA, Mahmoudi M, Edwards JY, Massicotte H, Cairns E, Bell DA.

Hum Antibodies Hybridomas. 1993 Jul;4(3):98-103.

PMID:
8357959

Supplemental Content

Loading ...
Support Center